Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
13.04.23
/
50%
€33.50
Target price
13.04.24
€59.72
Performance (%)
-29.85%
End price
14.04.24
€23.50
Summary
This prediction ended on 14.04.24 with a price of €23.50. The prediction for Intellia Therapeutics Inc disappointed with a performance of -29.85%. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -3.048% | -3.048% | -39.066% |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten